DOCUMENTS
Currently, we only publish our documents in Swedish.
PRESS RELEASES
Subscribe here to press releases.
MANAGEMENT
-
Victoire Viannay, Chief Executive Officer
CEO since 2017.
Born in 1975.
Previously the COO of Fluicell AB, Victoire is now the CEO. She holds a PhD in Law from Université Paris II Panthéon/Assas. Former Legal & HR Assistant Manager at Institut Curie, former Project Leader at Chalmers University of Technology, former Chief HR and Legal Officer at PSL Research University, Victoire has more than 10 years of experience in labor laws, human resources and legal management, particularly in the field of scientific research.
Owns 7,500 shares personally.
-
Gavin D. M. Jeffries, Chief Technology Officer
CTO since 2017.
Born in 1980.
Currently the CTO of Fluicell AB, Gavin has a PhD in Chemistry from the University of Washington, Seattle. He was Assistant Professor at Chalmers University for 4 years and has published over forty peer reviewed scientific publications, with a total citation count of over a thousand. Entrepreneur/founder of two biotech and optics companies, inventor of multiple patents and technologies, Gavin has a strong background in microfluidics, single-cell analysis and optical platform integration. Gavin has published over forty research articles.
Owns 50.285 shares personally and 185.000 shares through Jeffries and Associates AB.
-
Tatsiana Lobovkina, Chief Scientific Officer
CSO since 2018.
Born in 1975 .
Tatsiana is the CSO of Fluicell AB and Assistant Professor at Chalmers University of Technology, Gothenburg. After completing a PhD in chemistry from Chalmers, she completed three years of postdoctoral studies at Stanford University in the USA. With more than 10 years of experience as a research scientist, Tatsiana has a strong background in biophysics and biomimics and has published many scientific publications in international journals.
Currently doesn't own shares.
-
Mats Jonasson, Chief Financial Officer
CFO since 2016.
Born in 1956.
Mats is presently the CFO of Fluicell AB via Business Control Partner Norden AB. He studied economy at Gothenburg University, and has, for over 20 years, worked as CFO at companies, such as TiFiC AB and NTEX AB.
Currently doesn't own shares.
BOARD OF DIRECTORS
-
Stefan Tilk
Chairman of the board since 2016.
Born 1964.
Stefan Tilk is currently the Vice Chairman and group CEO at NEVS AB. He has a Master’s degree in Engineering Physics from Chalmers University of Technology and studied Business Administration in Barcelona School of Economics. Stefan has extensive experience, leading and developing companies as a CEO, including Geveko AB and Elof Hanson Group. Former Senior Executive Vice President for both Volvo Buses and Volvo Trucks, former Executive Vice President at Coor, Stefan has a strong business development background, skilled in negotiation, business planning, operations management, sales, and international business.
Owns 30,000 shares through STILK AB.Independent in relation to the company and major shareholders.
-
Owe Orwar
Board member since 2015.
Born 1964.
Owe is the CEO of Oblique Therapeutics and Senior Group Leader at the Karolinska Institute. After completing a PhD in chemistry from Gothenburg University, he completed two years of postdoctoral studies at Stanford University.
Former Global VP of R&D at Sanofi, former President of R&D at Piramal Healthcare, entrepreneur/founder and inventor of six biotech companies, Owe has over 20 years of experience in the pharma and biotech industry. Holder of more than 75 patents, author of hundreds of research articles, he is a pioneer in the fields of single-cell biology and biophysics with several products on the global market.Owns 113.995 shares through Clavis & Vose Invest AB.
Dependent in relation to the company / Independent in relation to major shareholders.
-
Gavin D. M. Jeffries
Board member since 2012.
Born in 1980.
Currently the CTO of Fluicell AB, Gavin has a PhD in Chemistry from the University of Washington, Seattle. He was Assistant Professor at Chalmers University for 4 years and has published over forty peer reviewed scientific publications, with a total citation count of over a thousand. Entrepreneur/founder of two biotech and optics companies, inventor of multiple patents and technologies, Gavin has a strong background in microfluidics, single-cell analysis and optical platform integration. Gavin has published over forty research articles.
Owns 50.285 shares personally and 185.000 shares through Jeffries and Associates AB.
Dependent in relation to the company / Independent in relation to major shareholders.
-
Daniel T. Chiu
Board member since 2017.
Born 1972.
Education at Harvard University, Stanford University and UC Berkeley.
Daniel has been Professor of Chemistry and Bioengineering at the University of Washington since 2006. After graduating from Stanford University, he completed postdoctoral research at Harvard University.
Scientific Founder of multiple Life Sciences/Biomedical companies across Asia, Europe, and U.S.A Member/Chair of numerous advisory and review panels for government and industry, he is a pioneer in the field of single-cell biology with several products on the global market. Daniel has authored more than 200 scientific publications and is the inventor on over 60 issued patents.Owns 30,000 shares personally.
Independent in relation to the company and major shareholders.
-
Carl Fhager
Board member since 2017.
Born in 1975.
Master of Laws, University of Gothenburg.
Carl is an experienced and recognized lawyer at MAQS’ Gothenburg office. He has extensive experience of commercial agreements, including ones relating to cooperation, commission, and purchasing, as well as to terms and conditions. He specializes in sports, media, and the entertainment industry in which he has worked for over ten years, in addition to being the sports director of the football club BK Häcken four years. Considering Carl’s dual legal and managerial background, has led him to assist many boards in an advisory manner, or to join them as a member or a chairman.
Currently doesn't own shares.
Independent in relation to the company and major shareholders.
Scientific Advisory Board
-
Astrid Brodd
Dr. Astrid Brodd is a licensed physician who studied at the University of Toulouse and at the Sahlgrenska Academy of the University of Gothenburg. She is a board-approved dermatologist since 1993 and started the dermatology clinic at the Carlanderska hospital in 1998. Dr. Astrid Brodd is active at Diagnostiskt Centrum Hud in Gothenburg. She has extensive clinical experience both from work in Sweden and internationally.
-
Göran Gannedahl
Dr. Göran Gannedahl is a licensed physician and Ph.D who studied at the Karolinska Institute and the University of Uppsala. He is a board-approved surgeon. Dr. Gannedahl has a vast experience of drug development in different therapeutic areas from leading positions in companies such as Novartis and AstraZeneca. He is the Chief Medical Officer at Oblique Therapeutics in Gothenburg.
-
Michael Olausson
Prof. Michael Olausson is a licensed physician and Ph.D who studied at the Sahlgrenska Academy of the university of Gothenburg. He is a board-certified specialist in transplantation surgery. Professor Olausson has been active as a transplantation surgeon at the Sahlgrenska Academy and Sahlgrenska University hospital since 1987. He is the founder and chairman of the Sahlgrenska Transplant Institute and is the author of more than 300 research papers and book chapters. Professor Olausson is a pioneer in the area of transplantation surgery and has introduced and conducted new innovative therapies as first in the world, first in Europe, first in Scandinavia and first in Sweden.
CALENDAR
| 2023-11-17 | Kvartalsrapport 3, 2023 |
| 2024-02-23 | Bokslutskommuniké, 2023 |
| Tidigare datum | |
| 2022-02-23 | Bokslutskommuniké 2021 |
| 2022-05-12 | Kvartalsrapport 1, 2022 |
| 2022-05-17 | Årsstämma 2022 |
| 2022-08-18 | Kvartalsrapport 2, 2022 |
| 2022-09-30 | Extra bolagsstämma |
| 2022-11-30 | Kvartalsrapport 3, 2022 |
| 2023-04-21 | Årsredovisning 2022 |
| 2023-02-24 | Bokslutskommuniké, 2022 |
| 2023-05-12 | Kvartalsrapport 1, 2023 |
| 2023-05-17 | Årsstämma 2023 |
| 2023-08-18 | Kvartalsrapport 2, 2023 |
INFORMATION ABOUT SHAREHOLDERS
2019/09/30
| Owner Name | Ownership | Voting Rights |
|---|---|---|
| Avanza Pension | 1 713 015 | 6,99 % |
| Viola Vitalis AB | 1 095 553 | 4,47 % |
| von der Osten-Sacken, Bernhard | 897 276 | 3,66 % |
| Nordnet Pensionsförsäkring AB | 545 300 | 2,23 % |
| Börjesson, Håkan | 491 796 | 2,01 % |
| Adamsson, Sten | 416 250 | 1,70 % |
| Futur Pension Försäkringsaktiebolag | 313 107 | 1,28 % |
| Jeffries and Associates AB & G Jeffries | 300 000 | 1,22 % |
| Åkerström, Per | 300 000 | 1,22 % |
| Larsson, Erik | 299 342 | 1,22 % |
| Other owners | 18 120 893 | 73,99 % |
| Total | 24 492 532 | 100 % |
CERTIFIED ADVISOR
Mangold Fondkommission AB tel. +46 8-503-015-50
NASDAQ FIRST NORTH GROWTH MARKET
Nasdaq First North Growth Market is a registered SME growth market, in accordance with the Directive on Markets in Financial Instruments (EU 2014/65) as implemented in the national legislation of Denmark, Finland and Sweden, operated by an exchange within the Nasdaq group. Issuers on Nasdaq First North Growth Market are not subject to all the same rules as issuers on a regulated main market, as defined in EU legislation (as implemented in national law). Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in an issuer on Nasdaq First North Growth Market may therefore be higher than investing in an issuer on the main market. All issuers with shares admitted to trading on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The respective Nasdaq exchange approves the application for admission to trading.